Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.58 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.58 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.58 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009420 | 0.90 | MAPT (0.63) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL4008089 | 0.86 | MEN1 (0.60) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL4548071 | 0.85 | EPHX2 (0.85) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL12010905 | 0.85 | CA12 (0.71) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL12010912 | 0.85 | NR1H3 (0.68) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL12010881 | 0.84 | MEN1 (0.68) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL9486707 | 0.84 | MEN1 (0.65) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL9913185 | 0.84 | CA12 (0.73) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL29039874 | 0.83 | HSD11B1 (0.62) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL28729179 | 0.82 | EPHX2 (1.00) | MAPTCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010053829-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | claimed |
| CN-101516838-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-08-26 | — | — | CN | claimed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | claimed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| EP-2069294-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008039999-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2010053829-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-2069294-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008039999-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039999-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | MAPT 3633/4885CA12 3893/4885CA1 3340/4885 |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | MAPT 4632/4885CA12 3574/4885CA1 2710/4885 |
| US-20080207622-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | MAPT 4703/4885CA12 2404/4885CA1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.